The core features of schizophrenia (SCZ) include cognitive deficits and impaired sensory gating represented by P50 inhibition deficits, which appear to be related to the α7 nicotinic acetylcholine receptor (nAChR). An agonist of nAChR receptor may improve these defects. This study aimed to investigate how administering multiple doses of tropisetron, a partial agonist of nAChR, for 1 day would affect cognitive deficits and P50 inhibition deficits in SCZ patients. We randomized 40 SCZ non-smokers into a double-blind clinical trial with four groups: placebo, 5 mg/d, 10 mg/d, and 20 mg/d of oral tropisetron. Their P50 ratios were all more than 0.5 and they took risperidone at 3–6 mg/day for at least a month before participating in the experiment. We measured the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and P50 inhibition before and one day after treatment. After one day of treatment, the total RBANS scores of the 20 mg and 5 mg tropisetron groups, and the immediate memory of the 10 mg group were significantly higher than placebo group. The P50 ratio was smaller in the 5 mg and 10 mg groups than in the placebo group (both p < 0.05) after treatment. Furthermore, the improvement in RBANS total score was correlated with increased S1 latency (p < 0.05), and the increase in immediate memory score was correlated with decreased S2 amplitude. One day of treatment with tropisetron improved both cognitive and P50 inhibition deficits, suggesting that longer term treatment with α7 nAChR agonists for these deficits in SCZ may be promising.
Subscribe to Journal
Get full journal access for 1 year
only $38.38 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Kanchanatawan B, Hemrungrojn S, Thika S, Sirivichayakul S, Ruxrungtham K, Carvalho AF, et al. Changes in Tryptophan Catabolite (TRYCAT) pathway patterning are associated with mild impairments in declarative memory in schizophrenia and deficits in semantic and episodic memory coupled with increased false-memory creation in deficit schizophrenia. Mol Neurobiol. 2018;55:5184–201.
Vohringer PA, Barroilhet SA, Amerio A, Reale ML, Alvear K, Vergne D, et al. Cognitive impairment in bipolar disorder and schizophrenia: a systematic review. Front Psychiatry. 2013;4:87.
Khalil AH, El-Meguid MA, Bastawy M, Rabei S, Ali R, Abd Elmoneam MHE. Correlating cognitive functions to symptom domains and insight in Egyptian patients with schizophrenia. Int J Soc Psychiatry. 2020;66:240–248.
Simonsen C, Sundet K, Vaskinn A, Birkenaes AB, Engh JA, Faerden A, et al. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group. Schizophr Bull. 2011;37:73–83.
Giraldo-Chica M, Rogers BP, Damon SM, Landman BA, Woodward ND. Prefrontal-thalamic anatomical connectivity and executive cognitive function in schizophrenia. Biol Psychiatry. 2018;83:509–17.
Hoonakker M, Doignon-Camus N, Bonnefond A. Sustaining attention to simple visual tasks: a central deficit in schizophrenia? A systematic review. Ann N. Y Acad Sci. 2017;1408:32–45.
Paquin K, Wilson AL, Cellard C, Lecomte T, Potvin S. A systematic review on improving cognition in schizophrenia: which is the more commonly used type of training, practice or strategy learning? BMC Psychiatry. 2014;14:139.
Schreiber R, Newman-Tancredi A. Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation. Neurobiol Learn Mem. 2014;110:72–80.
Neu P, Gooren T, Niebuhr U, Schlattmann P. Cognitive impairment in schizophrenia and depression: a comparison of stability and course. Appl Neuropsychol Adult. 2019;26:215–28.
Peralta V, Cuesta MJ. Social cognition in schizophrenia: the relevance of early detection and intervention. Sist Sanit Navar. 2017;40:173–75.
Dziwota E, Stepulak MZ, Wloszczak-Szubzda A, Olajossy M. Social functioning and the quality of life of patients diagnosed with schizophrenia. Ann Agric Environ Med. 2018;25:50–5.
Davidson M. Cognitive impairment as a diagnostic criterion and treatment target in schizophrenia. World Psychiatry. 2019;18:171.
Hamling KR, Schoppik D. Sensory gating: cellular substrates of surprise. Curr Biol. 2018;28:R871–3.
Lei Y, Ozdemir RA, Perez MA. Gating of sensory input at subcortical and cortical levels during grasping in humans. J Neurosci. 2018;38:7237–47.
Toyomaki A, Hashimoto N, Kako Y, Tomimatsu Y, Koyama T, Kusumi I. Different P50 sensory gating measures reflect different cognitive dysfunctions in schizophrenia. Schizophr Res Cogn. 2015;2:166–9.
Xia L, Yuan L, Du XD, Wang D, Wang J, Xu H, et al. P50 inhibition deficit in patients with chronic schizophrenia: relationship with cognitive impairment of MATRICS consensus cognitive battery. Schizophr Res. 2020;215:105–12.
Schubring D, Popov T, Miller GA, Rockstroh B. Consistency of abnormal sensory gating in first-admission and chronic schizophrenia across quantification methods. Psychophysiology. 2018;55:1–13.
Chien YL, Hsieh MH, Gau SS. P50-N100-P200 sensory gating deficits in adolescents and young adults with autism spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2019;95:109683.
Karkal R, Goyal N, Tikka SK, Khanande RV, Kakunje A, Khess CR. Sensory gating deficits and their clinical correlates in drug-free/drug-naive patients with schizophrenia. Indian J Psychol Med. 2018;40:247–56.
Koukouli F, Rooy M, Tziotis D, Sailor KA, O’Neill HC, Levenga J, et al. Nicotine reverses hypofrontality in animal models of addiction and schizophrenia. Nat Med. 2017;23:347–54.
Jones C. alpha7 nicotinic acetylcholine receptor: a potential target in treating cognitive decline in schizophrenia. J Clin Psychopharmacol. 2018;38:247–49.
Wadenberg MG, Manetti D, Romanelli MN, Arias HR. Significance of the nicotinic alpha7 receptor in cognition and antipsychotic-like behavior in the rat. Behav Brain Res. 2017;333:129–34.
Shiina A, Shirayama Y, Niitsu T, Hashimoto T, Yoshida T, Hasegawa T, et al. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry. 2010;9:27.
Hashimoto K. Targeting of α7 nicotinic acetylcholine receptors in the treatment of schizophrenia and the use of auditory sensory gating as a translational biomarker. Curr Pharm Des. 2015;21:3797–806.
Noroozian M, Ghasemi S, Hosseini SM, Modabbernia A, Khodaie-Ardakani MR, Mirshafiee O, et al. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology (Berl). 2013;228:595–602.
Poddar I, Callahan PM, Hernandez CM, Yang X, Bartlett MG, Terry AV Jr. Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine. Biochem Pharm. 2018;151:180–7.
Spilman P, Descamps O, Gorostiza O, Peters-Libeu C, Poksay KS, Matalis A, et al. The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer’s model. Brain Res. 2014;1551:25–44.
Hashimoto K, Iyo M, Freedman R, Stevens KE. Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of alpha 7 nicotinic acetylcholine receptors. Psychopharmacol (Berl). 2005;183:13–9.
Koike K, Hashimoto K, Takai N, Shimizu E, Komatsu N, Watanabe H, et al. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res. 2005;76:67–72.
Zhang XY, Liu L, Liu S, Hong X, Chen DC, Xiu MH, et al. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am J Psychiatry. 2012;169:974–81.
Chopko TC, Lindsley CW. Classics in chemical neuroscience: risperidone. ACS Chem Neurosci. 2018;9:1520–29.
Hong X, Chan RC, Zhuang X, Jiang T, Wan X, Wang J, et al. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia. Schizophr Res. 2009;108:151–7.
de Wilde OM, Bour L, Dingemans P, Koelman J, Linszen D. A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. Schizophr Res. 2007;97:137–51.
Dolu N, Suer C, Ozesmi C. A comparison of the different interpair intervals in the conditioning-testing P50 paradigms. Int J Psychophysiol. 2001;41:265–70.
Sánchezmorla EM, Santos JL, Aparicio A, Garcíajiménez MÁ, Soria C, Arango C. Neuropsychological correlates of P50 sensory gating in patients with schizophrenia. Schizophr Res. 2013;143:102–6.
Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20:310–9.
Zhang BH, Tan YL, Zhang WF, Wang ZR, Yang GG, Shi C, et al. Repeatable battery for the assessment of neuropsychological status as a screening test in Chinese: reliability and validity. Chin Ment Health J. 2008;22:865–69.
Cheng Y, Wu W, Wang J, Feng W, Wu X, Li C. Reliability and validity of the Repeatable Battery for the Assessment of Neuropsychological Status in community-dwelling elderly. Arch Med Sci. 2011;7:850–7.
Team RDC. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing. 2015.
Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008;165:1040–7.
Ishikawa M, Hashimoto K. α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia. Curr Pharm Des. 2011;17:121–29.
Boggs DL, Carlson J, Cortes-Briones J, Krystal JH, D’Souza DC. Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia. Curr Pharm Des. 2014;20:5077–92.
Hamilton HK, D’Souza DC, Ford JM, Roach BJ, Kort NS, Ahn KH, et al. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: implications for schizophrenia. Schizophr Res. 2018;191:87–94.
Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of α 7 nicotinic receptors. Biol Psychiatry. 2008;553:191–5.
Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biol Psychiatry. 2008;63:92–7.
Ishikawa M, Sakata M, Toyohara J, Oda K, Ishii K, Wu J, et al. Occupancy of α7 nicotinic acetylcholine receptors in the brain by tropisetron: a positron emission tomography study using [(11)C]CHIBA-1001 in healthy human subjects. Clin Psychopharmacol Neurosci. 2011;9:111–6.
Sagud M, Vuksan-Cusa B, Jaksic N, Mihaljevic-Peles A, Rojnic Kuzman M, Pivac N. Smoking in Schizophrenia: an Updated Review. Psychiatr Danub. 2018;30(Suppl 4):216–23.
Fond G, Berna F, Andrianarisoa M, Godin O, Leboyer M, Brunel L, et al. Chronic low-grade peripheral inflammation is associated with severe nicotine dependence in schizophrenia: results from the national multicentric FACE-SZ cohort. Eur Arch Psychiatry Clin Neurosci. 2017;267:465–72.
Dickerson F, Origoni A, Schroeder J, Adamos M, Katsafanas E, Khushalani S, et al. Natural cause mortality in persons with serious mental illness. Acta Psychiatr Scand. 2018;137:371–79.
Dickerson F, Stallings CR, Origoni AE, Vaughan C, Khushalani S, Schroeder J, et al. Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999–2011. Psychiatr Serv. 2013;64:44–50.
Zhang XY, Rao WW, Yu Q, Yu Y, Kou C, Tan YL, et al. Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with age of smoking initiation in male schizophrenia smokers. Am J Med Genet Part B Neuropsychiatr Genet. 2016;171:243–49.
Zhang XY, Li CB, Li M, Zheng YL, Zhang CX, Yan QZ, et al. Smoking initiation and schizophrenia: a replication study in a Chinese Han population. Schizophr Res. 2010;119:110–4.
Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacol (Berl). 2010;210:453–69.
Campos MW, Serebrisky D, Castaldelli-Maia JM. Smoking and cognition. Curr Drug Abus Rev. 2016;9:76–9.
Hong L, Schroeder M, Ross T, Buchholz B, Salmeron B, Wonodi I, et al. Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. Schizophr Bull. 2011;37:416–25.
Zhang XY, Tan YL, Chen DC, Tan SP, Yang FD, Zunta-Soares GB, et al. Effects of cigarette smoking and alcohol use on neurocognition and BDNF levels in a Chinese population. Psychopharmacol (Berl). 2015;233:435–45.
Tan SP, Jie-Feng C, Fan FM, Zhao YL, Chen N, Fan HZ, et al. Smoking, MATRICS consensus cognitive battery and P50 sensory gating in a Han Chinese population. Drug Alcohol Depend. 2014;143:51–7.
Choueiry J, Blais CM, Shah D, Smith D, Fisher D, Illivitsky V, et al. Combining CDP-choline and galantamine: Effects of a selective alpha7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers. J Psychopharmacol. 2019;33:688–99.
Leon JD, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76:135–57.
Turan T, Dolu N, Ozsoy S, Kılıç C, BeşİRli̇ A, Esel E. Effects of smoking on P50 waveform in schizophrenic patients. Klin Psikofarmakol Bul. 2009;19:227–35.
Winterer G. Why do patients with schizophrenia smoke? Curr Opin Psychiatry. 2010;23:112.
Liu H, Luo Q, Du W, Li X, Zhang Z, Yu R, et al. Cigarette smoking and schizophrenia independently and reversibly altered intrinsic brain activity. Brain Imaging Behav. 2018;12:1457–65.
Pesko MF, Baum CF. The self-medication hypothesis: evidence from terrorism and cigarette accessibility. Econ Hum Biol. 2016;22:94–102.
Kodaka F, Ito H, Takano H, Takahashi H, Arakawa R, Miyoshi M, et al. Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine. Int J Neuropsychopharmacol. 2011;14:83–9.
Hecht EM, Landy DC. Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis. Schizophr Res. 2012;134:202–6.
Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Todd L, Patel RC, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007;64:1115.
Liu DT, Zhuo KM, Song ZH, Yan WU, Chen XS, Wang JJ, et al. Effect of risperidone on sensory gating P50 deficit in patients with schizophrenia. J Shanghai Jiaotong Univ. 2010;30:1525–29.
Xu L, Song L, Zhang M, Chen X, Wu R, Tang J. A study on the effect of risperidone on PPI and P50 Deficit in FirstEpisode and chronic patients with schizophrenia. J Int Psychl. 2016;4:577–80.
Hashimoto K. Tropisetron and its targets in Alzheimer’s disease. Expert Opin Ther Targets. 2015;19:1–5.
Rahimian R, Fakhfouri G, Ejtemaei Mehr S, Ghia JE, Genazzani AA, Payandemehr B, et al. Tropisetron attenuates amyloid-beta-induced inflammatory and apoptotic responses in rats. Eur J Clin Invest. 2013;43:1039–51.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Xia, L., Liu, L., Hong, X. et al. One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia. Neuropsychopharmacol. 45, 1362–1368 (2020). https://doi.org/10.1038/s41386-020-0685-0
Sex-specific association between peripheral superoxide dismutase, BDNF and cognitive impairment in drug-naive first episode patients with schizophrenia
Free Radical Biology and Medicine (2020)